This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Nkarta (NKTX)

Tipranks - Tue Jun 23, 10:11AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Achieve Life Sciences (ACHV) and Nkarta (NKTX) with bullish sentiments.

TipRanks' Prime Week Sale - 70% Off

Achieve Life Sciences (ACHV)

In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Achieve Life Sciences, with a price target of $12.00. The company’s shares closed last Monday at $5.33, close to its 52-week high of $5.59.

According to TipRanks.com, Folkes is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -2.9% and a 36.4% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Rani Therapeutics Holdings, and Connect Biopharma Holdings. ;'>

Currently, the analyst consensus on Achieve Life Sciences is a Strong Buy with an average price target of $13.20.

See Insiders’ Hot Stocks on TipRanks >>

Nkarta (NKTX)

Mizuho Securities analyst Salim Syed maintained a Buy rating on Nkarta today and set a price target of $12.00. The company’s shares closed last Monday at $2.81, close to its 52-week low of $1.31.

According to TipRanks.com, Syed is a 1-star analyst with an average return of -1.0% and a 42.9% success rate. Syed covers the Healthcare sector, focusing on stocks such as Maze Therapeutics, Inc., Syndax Pharmaceuticals, and Atara Biotherapeutics. ;'>

Nkarta has an analyst consensus of Strong Buy, with a price target consensus of $11.80.

Read More on ACHV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.